Abstract
The use of dalbavancin as a suppressive treatment is describe but not with therapeutic drug monitoring during a suppressive treatment. Our patient benefit of 20 month treatment of suppressive therapy with dalbavancin (1500 mg at each administration).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Open Journal of Clinical & Medical Case Reports
Paper Title
Journal
Date
